Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24300261 | 1.00 | PDE10A (0.37) | PDE10APPARDTP53MDM2MTOR | |
| SCHEMBL24300260 | 0.87 | PDE10A (0.35) | PDE10ATP53MDM2MTOR | |
| SCHEMBL25840630 | 0.86 | QPCT (0.34) | PDE10APPARDTP53MDM2MTOR | |
| SCHEMBL24300798 | 0.85 | PDE10A (0.39) | PDE10APPARDMTORQPCTQPCTL | |
| SCHEMBL25840046 | 0.85 | PDE10A (0.36) | PDE10APPARDTP53MDM2MTOR | |
| SCHEMBL28728598 | 0.84 | NT5E (0.36) | TP53MDM2MTORQPCTQPCTL | |
| SCHEMBL29467441 | 0.84 | NT5E (0.36) | TP53MDM2MTORQPCTQPCTL | |
| SCHEMBL24300262 | 0.83 | PPARD (0.33) | PDE10APPARDTP53MDM2MTOR | |
| SCHEMBL26527620 | 0.83 | TP53 (0.34) | PDE10ATP53MDM2MTORQPCT | |
| SCHEMBL28728563 | 0.82 | NT5E (0.36) | TP53MDM2MTORQPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4212524-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | Betta Pharmaceuticals Co., Ltd (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321100-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | ENTPD5, ENTPD1, NT5E | PDE10A 661/4885PPARD 3722/4885TP53 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.